Glucan-induced keratoderma in acquired immunodeficiency syndrome.
Six of 20 patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex receiving intravenous infusions of soluble glucan (beta-1-3 polyglucose) developed a keratoderma of the palms and soles. The eruption began during the first two weeks of therapy and resolved two to four weeks after its discontinuation. The eruption was different in appearance from our previously reported keratoderma blennorrhagica in AIDS-associated psoriasis. None of the other 735 patients with AIDS or AIDS-related complex not treated with soluble glucan developed a similar keratoderma. The correlation between receiving glucan and the hyperkeratosis is highly significant. Since glucan is a naturally occurring component of the cell walls of yeast, fungus, and some bacterial organisms, recognition of its ability to induce such a striking reaction pattern may be of general significance and interest, although the reaction itself may be limited to patients with AIDS.
D000386:AIDS-Related Complex / Q000628:therapy; D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D004341:Drug Evaluation; D005936:Glucans / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007645:Keratoderma, Palmoplantar / Q000209:etiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged
D000276:Adjuvants, Immunologic; D005936:Glucans